Wird geladen...
Administration of a Sigma Receptor Agonist Delays MCAO-Induced Neurodegeneration and White Matter Injury
Many pharmacological treatments for stroke have afforded protection in rodent models but failed to show efficacy in clinical trials. This discrepancy may be due to the lack of long-term functional studies. Previously, delayed administration of the sigma receptor agonist 1,3-di-o-tolylguanidine (DTG)...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2010
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2885737/ https://ncbi.nlm.nih.gov/pubmed/20563232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12975-009-0005-9 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|